InterVenn Biosciences Partners with Aranscia to Accelerate Commercialization of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test
PR Newswire —
Aranscia's Suite of Laboratory and Technology Solutions to Support InterVenn's Commercialization Program SOUTH SAN FRANCISCO, Calif. and HOUSTON, Jan. 7, 2026 /PRNewswire/ -- InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia,...